SCHEMBL25575151

SCHEMBL25575151

CC(=O)c1cscc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.46
PTPN1 P18031 1/20 0.45
CYP2C9 P11712 1/20 0.38
TSHR P16473 1/20 0.37
ALDH1A1 P00352 2/20 0.36
ALOX15 P16050 1/20 0.36
CYP1A2 P05177 1/20 0.36
KDM4E B2RXH2 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
NOTUM Q6P988 1/20 0.34
LCK P06239 1/20 0.34
FYN P06241 1/20 0.34
DAO P14920 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA4 P22748 2/20 0.34
CA7 P43166 2/20 0.34
CA9 Q16790 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL68448 0.87 PTPN1 (0.54) DHODHPTPN1CYP2C9TSHRALDH1A1
SCHEMBL28655905 0.84 PTPN1 (0.52) DHODHPTPN1CYP2C9TSHRALDH1A1
Acetic Acid SCHEMBL11480827 0.76 PTPN1 (0.42) DHODHPTPN1CYP2C9TSHRALDH1A1
SCHEMBL6804224 0.75
SCHEMBL1787147 0.75
SCHEMBL128959 0.75
SCHEMBL14397454 0.75 CYP2C9 (0.45) DHODHCYP2C9TSHRALDH1A1ALOX15
SCHEMBL22415683 0.75 MEN1 (0.37) TSHRALDH1A1KDM4ESMN1; SMN2GSK3B
SCHEMBL13913259 0.75 PTPN1 (0.46) DHODHPTPN1TSHRALDH1A1ALOX15
SCHEMBL1498198 0.73 PTPN1 (0.44) DHODHPTPN1CYP2C9TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230398226-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS CIDARA THERAPEUTICS, INC. 2023-12-14 US disclosed
US-11833213-B2 Compositions and methods for the treatment of viral infections CIDARA THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
US-20230287365-A1 COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2023-09-14 US disclosed
US-20230190950-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS CIDARA THERAPEUTICS, INC. 2023-06-22 US disclosed
US-20230165970-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS CIDARA THERAPEUTICS, INC. 2023-06-01 US disclosed
WO-2023074408-A1 THIOPHENE COMPOUND, METHOD FOR SYNTHESIZING SAME, AND COMPOSITION CONTAINING SAID THIOPHENE COMPOUND 四国化成工業株式会社 2023-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230398226-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS FCGR3B, ALB, FCGR1A DHODH 2887/4885PTPN1 1028/4885CYP2C9 1573/4885
US-20230190950-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS FCGR3B, FCGR1A, FCGR2A DHODH 3518/4885PTPN1 499/4885CYP2C9 3373/4885
US-11833213-B2 Compositions and methods for the treatment of viral infections FCGR3B, ALB, FCGR1A DHODH 2887/4885PTPN1 1028/4885CYP2C9 1573/4885
US-20230165970-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS FCGR3B, FCGR1A, FCGR2A DHODH 3518/4885PTPN1 499/4885CYP2C9 3373/4885
US-20230287365-A1 COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION ENTPD1, ENTPD2, ENTPD5 DHODH 1101/4885PTPN1 764/4885CYP2C9 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.